Amgen Inc. $AMGN Shares Purchased by Farther Finance Advisors LLC

Key Points

• Farther Finance Advisors LLC boosted its stake in Amgen by 65.5% in Q4, adding 11,156 shares to hold 28,191 shares worth about $9.23 million at quarter-end.
• Amgen beat Q4 estimates with EPS $5.29 versus $4.76 expected and revenue of $9.87 billion versus $9.46 billion, and it set FY2026 guidance of 21.600–23.000 EPS.
• The company declared a quarterly dividend of $2.52 per share (annualized $10.08), implying a yield of about 2.9%; the ex-dividend date and record date are May 15 and the dividend will be paid June 5.

Farther Finance Advisors LLC increased its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 65.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 28,191 shares of the medical research company's stock after acquiring an additional 11,156 shares during the quarter. Farther Finance Advisors LLC's holdings in Amgen were worth $9,227,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Board of the Pension Protection Fund acquired a new stake in shares of Amgen during the 4th quarter worth approximately $26,000. Olistico Wealth LLC acquired a new stake in shares of Amgen during the 4th quarter worth approximately $33,000. Cloud Capital Management LLC acquired a new stake in shares of Amgen during the 3rd quarter worth approximately $34,000. Saranac Partners Ltd acquired a new stake in shares of Amgen during the 3rd quarter worth approximately $37,000. Finally, Holos Integrated Wealth LLC acquired a new stake in shares of Amgen during the 4th quarter worth approximately $37,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Stock Performance

Shares of AMGN stock opened at $348.22 on Thursday. Amgen Inc. has a 12-month low of $261.43 and a 12-month high of $391.29. The firm has a market capitalization of $187.93 billion, a price-to-earnings ratio of 24.47, a price-to-earnings-growth ratio of 3.30 and a beta of 0.47. The business has a 50 day simple moving average of $363.86 and a 200 day simple moving average of $336.66. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $4.76 by $0.53. The business had revenue of $9.87 billion during the quarter, compared to analyst estimates of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The business's revenue for the quarter was up 8.6% compared to the same quarter last year. During the same period in the prior year, the company posted $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, equities research analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be paid a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date of this dividend is Friday, May 15th. Amgen's dividend payout ratio (DPR) is presently 70.84%.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on AMGN shares. Rothschild & Co Redburn increased their price target on Amgen from $180.00 to $200.00 and gave the stock a "sell" rating in a research report on Wednesday, February 18th. Leerink Partners reiterated a "market perform" rating and set a $355.00 price target on shares of Amgen in a research report on Thursday, March 5th. Barclays began coverage on Amgen in a research report on Friday, February 20th. They set an "equal weight" rating and a $350.00 price target on the stock. Cantor Fitzgerald reissued a "neutral" rating and issued a $350.00 price objective on shares of Amgen in a report on Wednesday, April 8th. Finally, The Goldman Sachs Group increased their price objective on Amgen from $403.00 to $415.00 and gave the stock a "buy" rating in a report on Wednesday, February 4th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have given a Hold rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat, Amgen presently has an average rating of "Hold" and an average target price of $356.24.

Amgen Company Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.